

Grifols launches new home-care treatment service for patients with alpha-1 antitrypsin deficiency in Spain

- *The new service will include the administration of the intravenous treatments in patients' homes by a healthcare professional, avoiding a trip to the hospital*
- *This offering is part of Grifols' AlfaCare, a comprehensive, personalized assistance program for patients with alpha-1 antitrypsin deficiency, including training, emotional support and tailored attention through specialized professionals*
- *This pioneering program in Spain has more than 200 patients and now broadens its resources to include a nursing team skilled in home care*

Barcelona, Spain, November 24, 2021 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 110-year track record of contributing to the health and well-being of people around the world, today announced a new home-infusion treatment service for patients with alpha-1 antitrypsin deficiency (AATD) in Spain.

This new service aims to increase treatment access and the comfort of its administration within Grifols' AlfaCare program. It offers an integrated, personalized program including training, emotional support and assistance to AATD patients through specialized professionals.

Grifols began AlfaCare in Spain three years ago, with the support of the Alpha-1 patient association in Spain. Since then it has demonstrated benefits in the promotion of self-care and the improvement in patients' quality of life.

The program, which already offers training with respiratory physiotherapists and emotional support from psychologists, now incorporates administration of the intravenous treatment at home, which will eliminate travel time and waiting in hospitals. The first patients are already benefiting from the service and it is expected that others will enroll in the upcoming months.

AATD is a rare genetic disease defined by a deficiency or absence of the alpha-1 antitrypsin protein in the blood. It is the most common cause of severe pulmonary emphysema and chronic obstructive pulmonary disease (COPD) in adults, in addition to being the most common cause of liver disease in children. AATD symptoms vary depending on the degree of severity and type of genetic mutation, as well as on external

GRIFOLS

factors. It is estimated that AATD affects 3.4 million people around the world¹ and 14,500 in Spain².

“AlfaCare is part of Grifols’ commitment to improve quality of patients’ lives,” said Joana Sabat, vice president Global Marketing, Bioscience Division. “In collaboration with patient associations, we will improve the knowledge and diagnosis of diseases such as alpha-1 antitrypsin deficiency. It is critical to recognize its prevalence, and know how to diagnose it and treat it.”

Grifols’ commitment to caring for AATD patients through the educational support program and at-home therapy administration complements the company’s research activity in the field, which is focused on developing new early diagnosis tests and new approaches to treating the disease.

Grifols has similar support programs for patients with AATD in other countries such as Italy, Canada and the United States.

About AATD

AATD is a rare hereditary disease defined by a deficiency or absence of the alpha-1 antitrypsin protein in plasma. It is the most common cause of severe pulmonary emphysema and chronic obstructive pulmonary disease (COPD) in adults, as well as the most common cause of liver disease in children.

This illness is more prevalent than other rare lung diseases such as cystic fibrosis and pulmonary arterial hypertension. AATD symptoms vary depending on the degree of severity and type of genetic mutation, as well as external factors.

AATD affects some 3.4 million people around the world, although most do not know they have it. In Spain, it is estimated that about 14,500 people have the disease.

For more information about alpha-1 antitrypsin deficiency, please visit: www.alpha1.org.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

¹ de Serres F. J. (2003). *Alpha-1 antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosed. Environmental health perspectives*, 111(16), 1851–1854.

² Blanco, I., Bueno, P., Diego, I., Pérez-Holanda, S., Casas-Maldonado, F., Esquinas, C., y Miravittles, M. (2017). *Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update. International journal of chronic obstructive pulmonary disease*, 12, 561–569.

GRIFOLS

Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2019, Grifols' economic impact in its core countries of operation was EUR 8.5 billion. The company also generated 148,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit www.grifols.com

Media contact:

Media Press Office

media@grifols.com

Tel. +34 571 00 02

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.